

# Immune-mediated neuropathies:

How to identify in an ocean of  
polyneuropathies?

**Rayomand Press**  
**Neuromuscular Unit**  
**Department of Neurology & Institution for Clinical Neuroscience**  
**Karolinska University Hospital**  
**Stockholm**


# Specialized neuromuscular centers in Sweden

All regions care for their own patients with neuromuscular diseases, but refer advanced cases to the university hospitals in:

- Lund/Malmö (SUS)
- Göteborg (Sahlgrenska)
- Linköping (US)
- Stockholm (Karolinska). *Population base 2.3 milj*


Metabolic / mitochondrial diseases and pediatric cases:

- Göteborg & Stockholm



# Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Patient overview in Swedish Neuro Registries ([www.neuroreg.se](http://www.neuroreg.se))



# Immune-mediated neuropathies


## Definition

- Inflammatory disorders of the PNS (+ rarely even CNS simultaneously)
- Treatable neuropathies


## Contents

- Classification of immune-mediated neuropathies
- The pattern recognition approach to investigating neuropathies
- Acute onset neuropathies diff. diagnosis  
including pan-neurofascin autoimmune nodopathy
- Chronic immune-mediated neuropathies  
CIDP, MMN and paraproteinemic neuropathies & diff. diagnosis

# 9-30% of all neuropathies are immune-mediated



Visser et al., Neurology, 2015;84 :259-264



Mygland & Monstad, Eur J Neurol 2001; 2001 8:157-65.

-> **27% of "idiopathic" neuropathies** referred to the 3<sup>o</sup> center at Columbia, NY had an inflammatory etiology (CIDP, IgMGUS, Sjögren ...)

**USA**

Farhad et al. Muscle & Nerve 2016

| Cause of peripheral neuropathy                              | Number of patients  | Percent |
|---|---|---------|
| Idiopathic  | 19  | 19%     |
| Diabetes mellitus   | 17  | 17%     |
| Vitamin B12 deficiency                                      | 9   | 9%      |
| Dysimmune neuropathies                                      |   |         |
| Associated or not with autoimmune disease (other than CIDP) | 7 + 3 associated with autoimmune disease (1 vasculitis, 2 connective tissue diseases) | 7% + 3% |
| CIDP  | 8   | 8%      |
| Paraproteinemia-related neuropathy                          | 8   | 8%      |
| Celiac disease  | 6   | 6%      |
| Multifocal motor neuropathy (MMN)                           | 3   | 3%      |
| Paraneoplastic neuropathy                                   | 3   | 3%      |
| Hypothyroidism  | 6   | 6%      |
| Toxic causes  | 4   | 4%      |
| Genetic polyneuropathy                                      | 3   | 3%      |
| Infective causes  | 2   | 2%      |
| Alcohol   | 1   | 1%      |
| Chronic kidney disease                                      | 1   | 1%      |
| Total   | 100   |         |

**Italy 30%**

Ricci et al. Neurol Sci 2019



# Inflammatory neuropathies – Etiologies

## SECONDARY Systemic

### Systemic diseases

Sjögren, sarcoidosis,...  
Paraproteinemia (DADS)  
Non-Hodgkin lymphoma  
Osteosclerotic myeloma (POEMS)

### Immunotherapy-related

Anti-TNF- $\alpha$   
Tacrolimus  
Immune checkpoint inhibitors  
GVHD-neuropathy

### Paraneoplastic


Anti-Hu, CASPR2 ....

## PRIMARY Non-systemic

GBS  
CIDP  
MMN  
PNS-vasculitis

### Autoimmune nodopathies



- Chronic: CIDP-like
- Acute: GBS-like  
Pan-neurofascin  
autoimmune nodopathy



# The Pattern Recognition approach: aid in the etiological hunt

**History**  
**Nerve exam**  
**Neurophysiology**

**Pool  
of all  
neuropathies**



**CSF analysis**  
**Nerve imaging**  
**Antibody testing**  
**Nerve biopsy**

Published in final edited form as:

*Neurol Clin.* 2013 May ; 31(2): 343–361. doi:10.1016/j.ncl.2013.02.001.

## Pattern Recognition Approach to Neuropathy and Neuronopathy

**Richard J Barohn, M.D.<sup>a</sup> and Anthony A. Amato, M.D.<sup>b</sup>**

<sup>a</sup>Chairman, Department of Neurology, and Gertrude and Dewey Ziegler Professor of Neurology, University of Kansas Medical Center, Kansas City, Kansas

<sup>b</sup>Vice-chairman, Department of Neurology, Brigham and Women's Hospital, Professor of Neurology, Harvard Medical School, Boston, MA

## Peripheral Neuropathy: Asking the Right Questions

Careful evaluation can reveal the cause of  
peripheral neuropathy in more than half of all cases.

By Charlene Hoffman-Snyder NP-BC and Benn Smith MD  
*Practical Neurology*, 2009

**Immune-  
mediated  
neuropathy**



**Other  
etiologies**



**Karolinska Polyneuropati  
Vårdprogram 2021**  
**[www.snema.se](http://www.snema.se)**

## Features which set inflammatory neuropathies apart

- Acute/subacute onset, relapsing-remitting course
- Demyelinating polyneuropathy (differential CMT1)
- Unusual neuropathy phenotypes / patterns:
  - Proximal muscle weakness
  - Pure sensory
  - Pure motor
  - Asymmetrical (mononeuritis multiplex)
- Systemic features
  - Paraprotein (IgM >> IgG > IgA)
  - Systemic inflammatory disease
  - Malignancy
  - Use of drugs which induce autoimmunity



# Patterns based on mode of onset and course of disease

Lehmann et al. *Neurological Research and Practice*  
<https://doi.org/10.1186/s42466-020-00064-2>

(2020) 2:20


Neurological Research  
and Practice

## STANDARD OPERATING PROCEDURE

Open Access

## Diagnosis of peripheral neuropathy

Helmar C. Lehmann<sup>1\*</sup>, Gilbert Wunderlich<sup>1,2</sup>, Gereon R. Fink<sup>1,3</sup> and Claudia Sommer<sup>4</sup>



# Patterns based on neurophysiological findings

## Pure sensory axonal features

↓ SNAP amplitudes


### Dorsal root ganglia

Ganglionopathy  
- Paraneoplastic  
- Sjögren

QST  
↑ warm  
& cold  
thresholds

### Unmyelinated fibers

Vasculitis, Sjögren, Sarcoidosis



## Demyelinating features

Slow NCV, conduction blocks, prolonged F-waves

### Proximal roots/distal myelin

GBS (AIDP)  
CIDP  
Autoimmune nodopathies  
MMN  
DADS (PDN)

## Axonal features

↓ CMAP/SNAP

### Axon

GBS (AMAN /AMSAN)  
Vasculitis  
Sarcoidosis  
Paraneoplastic

# Patterns based on mode of onset vs. neurophysiological findings

## Acute

## Chronic

### Demyelinating

#### AIDP (GBS)

Acute-CIDP

Panneurofascin  
autoimmune nodopathy

#### - CIDP

- MMN

- Paraprotein-related  
neuropathy

### Axonal

- AMAN

- AMSAN

= Axonal GBS

- Vasculitic neuropathy

- Paraneoplastic  
neuropathies

GBS = Guillain-Barré syndrome



MMN = Multifocal Motor Neuropathy

AM(S)AN = Acute Motor (Sensory) Axonal Neuropathy

CIDP = Chronic Inflammatory Demyelinating Polyradiculoneuropathy

# Patterns based on topography and type of symptoms

## The typical **non-inflammatory** polyneuropathies




Slowly progressive  
Sensorymotor  
**Axonal** or demyelinating

### Etiologies


Diabetes, B-vit deficiency, toxic, CMT, ATTRv amyloidosis,...  
25% are chronic idiopathic axonal polyneuropathies (**CIAP**)

# Patterns based on topography and type of symptoms

## The typical inflammatory polyneuropathies



**GBS**  
**CIDP**



**MMN**  
**MADSAM**  
**Vasculitis**




**Pure**  
**sensory**  
**neuropathy**



# Differential diagnosis of multifocal neuropathies

Based on clinical and neurophysiological findings




*MADSAM: Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (CIDP-variant)*


*HNPP: Hereditary Neuropathy with Pressure Palsies*

# Pure sensory neuropathies- *based on electrophysiological findings*

**Axons: A $\alpha$  and A $\beta$  fibers**



**C- and A $\delta$  fibers**



**Dorsal root ganglia**



**Neuro-  
physiology**

**Pure sensory  
axonal** symmetrical  
neuropathy

Normal ENeG  
**Small Fiber Neuropathy (SFN)**

Pure sensory axonal  
patchy neuropathy

SNAP

Reduced

Pathol QST

Normal

**Ganglionopathy**

Reduced

**Nerve exam**

**Areflexia**  
Sensory ataxia

**Normoreflexia**  
Allodynia  
Autonomic

**Normoreflexia**  
Hypoesthesia  
No sensory ataxia

**Etiologies**

Vasculitis (Sjögren...), sarcoidosis, paraneoplastic, postinfectious, covid vaccine  
Genetic: HSAN, CANVAS

# **Acute onset neuropathies**



# Differential diagnosis of acute onset neuropathies

## ■ Toxic

- Chemotherapy-induced axonal neuropathy
- GBS-like onset axonal + demyelin.: Amiodarone, nitrofurantoin, vincristine
- Lead poisoning

## ■ Metabolic

Porphyria

## ■ Immune-mediated

- Guillain-Barré Syndrome (GBS)  
AIDP, AMAN/AMSAN, Miller-Fisher Syndrome
- Acute-CIDP
- Acute post-infectious (post-vaccination) small fiber neuropathy (SFN)
- Pan-neurofascin autoimmune nodopathy

# Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy


Helena Stengel, Atay Vural, MD, PhD, Anna-Michelle Brunder, Annika Heinius, Luise Appeltshauser, MD, Bianca Fiebig, Florian Giese, MD, Christian Dresel, MD, Aikaterini Papagianni, MD, Frank Birklein, MD, PhD, Joachim Weis, MD, Tessa Huchtemann, MD, Christian Schmidt, MD, Peter Körtvelyessy, MD, Carmen Villmann, PhD, Edgar Meinl, MD, Claudia Sommer, MD, PhD, Frank Leypoldt, MD,\* and Kathrin Doppler, MD\*

**Correspondence**  
Dr. Doppler  
Doppler\_K@ukw.de

*Neurol Neuroimmunol Neuroinflamm* 2019;6:e603. doi:10.1212/NXI.0000000000000603

*J Neurol Neurosurg Psychiatry* 2021;92:1089–1095.

## IgG<sub>1</sub> pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality

Janev Fehmi ,<sup>1</sup> Alexander J Davies,<sup>1</sup> Jon Walters,<sup>2</sup> Timothy Lavin,<sup>3</sup> Ryan Keh,<sup>3</sup>

## Pan-Neurofascin autoimmune nodopathy – a life-threatening, but reversible neuropathy

---

Luise Appeltshauser and Kathrin Doppler

---

Current Opinion in Neurology, 36 (5), 394-401. 2023



# Autoimmune nodopathies


Antibody-mediated disease where adhesion molecules are attacked at the nodes and paranodes

Subtypes: Acute and chronic


## Pan-neurofascin nodopathy (acute)


**Diagnosis: Serum antibodies to NF-155, -186 and -140**

- GBS-like acute onset
- Tetraplegia, cranialnerve paresis
- Autonomic failure
- Respiratory failure
- Long-term invasive ventilation
- (Locked-in)
- High mortality
- Demyelinating + axonal
- Poor response to IVIg / PE
- Good response to rituximab
- Monophasic



# Differential diagnosis of acute onset sensorimotor immune-mediated neuropathies



A photograph of a hospital hallway. In the foreground, a dark-colored manual wheelchair is parked on the left side, facing away from the camera. It has a white cushion with colorful patterns on the seat. The hallway is long and narrow, with light-colored tiled floors and light blue walls. In the background, three people are walking away from the camera: a nurse in a white uniform and cap, a person in green scrubs, and another person in a white lab coat. The hallway is brightly lit, and the perspective leads the eye down the corridor.

# **Chronic neuropathies**

# Chronic Inflammatory Demyelinating Polyradiculoneuropathy - CIDP

Demyelinating motor and sensory polyneuropathy  
Subacute-, or acute onset!

Prevalence: 2-9/100,000; ♂ > ♀

Age of onset 4-90, median 50 yrs

**Associated** rarely with IgG paraprotein, lymphoma, GVHD and immune checkpoint inhibitors

## Signs:

- Motor weakness in all 4 extremities, including proximally
- Areflexia
- Progressive phase >8w


## Diagnosis:

- Neurophysiology
- CSF analysis and nerve imaging (supportive)

## Treatment:


IVIg, kortison, plasma exchange, cyclophosphamide, HSCT







# Differential diagnosis of subacute onset sensorimotor immune-mediated neuropathies



# Multifocal Motor Neuropathy (MMN)


Multifocal immune-mediated **demyelinating motor** neuropathy, often with multipel conduction blocks




Prevalence: 0.5 /10<sup>5</sup>, ♂>♀

- Onset often distally in one arm
- Asymmetrical spread
- Slow progression
- Hypo- or normoreflexia
- Muscle atrophy, fasciculations (diff: PSMA)
- Treatable: IVIg

## Diagnosis:

- ENeG: **Pure motor demyelinating** neuropathy, +/- conduction blocks
- S- GM1 IgM antibodies in up to 80% of cases
- Imaging: MRI or nerve ultrasound





# Paraprotein + polyneuropathy: Causality?

**IgM** paraproteins may induce an immune-mediated demyelinating neuropathy

**Associated with:** MGUS, lymphoma, Waldenström, Myeloma

**Mechanism:** Myelin-associated glycoprotein (MAG) antibodies. 50% of IgM parapr.


## Distal Acquired Demyelinating Symmetric Neuropathy (DADS)

Slowly progressive

Sensory > motor

Distal

Sensory ataxia, tremor



**ENeG:** *Demyelinating* neuropathy, extremely prolonged distal latencies

**Treatment:** Cortison, IVIg, Rtx

## Other paraproteins:

- **IgG-κ** -> No causality in chronic axonal neuropathies
- **IgG-λ and IgA-λ** -> POEMS -> Sensorimotor demyelinating + axonal PNP
- **Light chains** -> AL amyloidosis -> Severe sensorimotor axonal PNP

# Antibody testing

| <u>Condition</u>   | <u>Autoantibody (serum)</u>                       | <u>Clinical application</u>             |
|--|---|---|
| <b>MFS</b>   | anti-GQ1b   | 90% are seropositive                    |
| <b>Autoimmune nodopathy</b>                              | Neurofascin antibodies,<br>CASPR1, Contactin 1    | 100% are seropositive                   |
| <b>MMN</b>   | Anti-GM1 IgM                                      | 30-80% are seropositive                 |
| <b>DADS + IgM-κ paraprotein</b>                          | Anti-MAG  | Ca 50% are seropositive                 |
| <b>POEMS (IgG / IgA-λ)</b>                               | S-VEGF  | Yes (but low titers are unspecific)     |
| <b>Vasculitic neuropathy</b>                             | Vasculitis panel                                  | Yes                                     |
| <b>Ganglionopathy</b>                                    | SSA/SSB, anti-Hu<br>TS-HDS                        | Yes<br>Sometimes (moderate specificity) |
| <b>Subacute sensory and<br/>ataxic axonal neuropathy</b> | Anti-Hu, CV2,<br>amphiphysin,<br>Vasculitis panel | Yes                                     |



# Karolinska vårdprogram för utredning av polyneuropati (2021)

[www.snema.se/dokument](http://www.snema.se/dokument)

| PNP Kategori | Vanligaste orsak   | Förlopp - progress            | Sens / Motor/ Autonom       | Utbredning     | Neurofysiologiska fynd                                |
|--------------|--|-------------------------------|-----------------------------|----------------|---|
| 1            | <i>Idiopatisk</i>  | Mycket långsamt               | Sens >> Motor               | Distal         | Lätt axonal   |
| 2            | <i>Varierande:<br/>Systemiska sjuk / CMT mm</i>          | Långsamt                      | Sens ≥ Motor;<br>ev autonom | Distal >> Prox | Axonal eller<br>Axonal + demyelin.<br>(Ren Demyelin.) |
| 3            | <i>Immunologisk<br/>GBS / CIDP</i>                       | Akut<br>Subakut<br>(långsamt) | Motor ≥ Sens,<br>ev autonom | Distal ≥ Prox  | Demyelin. eller<br>Demyelin. + axonal                 |
| 4            | <i>Immunologisk<br/>MMN</i>                              | Subakut<br>Långsamt           | Motor                       | Distal > Prox  | Demyelin. eller<br>Demyelin. + axonal                 |
| 5            | <i>Bindvävs sjuk /<br/>Paramalign.</i>                   | Subakut<br>Långsamt           | Sens                        | Distal > Prox  | Axonal  |
| 6            | <i>Idiopatisk<br/>Fintrådsneurop.</i>                    | Subakut<br>Långsamt           | Sens, ev<br>autonom         | Distal         | Fintrådspåverkan                                      |
| 7            | <i>Vaskulit<br/>Mononeuritis<br/>Multiplex,<br/>HNPP</i> | Akut<br>Subakut<br>Långsamt   | Sens ≥ Motor                | Distal         | Axonal eller<br>Axonal + demyelin.                    |

Tid för debut av symtom till maximal-symtomnivå: =Akut: < 4 veckor; =Subakut: ca 2 månader- 1 år (3 år);  
Långsamt: ca 3-5 år; =Mycket långsamt: ca 6-15 år

| PNP Kategori | Etiologi  | Utredningsförslag   |
|--------------|---|---|
| 1            | Axonal degeneration som är idiopatisk, hereditär, åldersrelaterad, eller sekundär till diabetes, B-vitaminbrist, alkohol och toxiska faktorer   | Basala prover<br>ENeG/EMG utom hos "äldre-äldre"  |
| 2            | Axonal degeneration med sekundär myelinskada, alt primär demyelinisering med en sekundär axonal skada.<br>Ofta idiopatisk, men kan bero på systemiska sjukdomar såsom diabetes mellitus, njursvikt, vitaminbristtillstånd mm. Ärftliga tillstånd som ATTRv-amyloidosis samt både axonala och demyeliniserande former av CMT.<br>Toxiska orsaker som alkohol och läkemedel.<br>Systemiskt- eller isolerad PNP-vaskulit, IgM paraprotein, sekundär amyloidosis, lymfom, samt senstadium av CIDP där sekundär axonal degeneration överväger. | - Basala prover<br>- ENeG/EMG<br>- Ev. KST och/eller autonoma tester<br>- Ev. genetisk utredning (CMT)<br><br><b>Yngre pat + snabb progress även:</b><br>- Vaskulitprover (se kategori # 5!)<br>- Paramalignitetsutredning (se # 5!)<br>- Muskelbiopsi (vaskulit?)<br>- Fettbiopsi (amyloid?)<br>- U-elfores, anti-gangliosid antikroppar (ak) i serum<br>- Mutationsanalys- ATTRv-amyloidosis?<br>- Muskel, och ev. även nervbiopsi (vaskulit? Amyloidosis?) |
| 3            | Immunologiskt angrepp mot myelin i PNS  | Basala prover, ENeG/EMG<br>LP, ev MRT rygg + kontrast eller nervultraljud, ev MAG-antikroppar   |
| 4            | Immunologiskt angrepp mot myelin i PNS  | Basala prover, ENeG/EMG<br>LP, anti-gangliosid ak i serum. Ev nervultraljud   |
| 5            | Axonal degeneration i grova sensoriska nervfibrer inklusive de proprioceptiva banorna.<br>Bakomliggande orsaker är bindvävssjukdom (oftast Sjögrens syndrom) samt paramalignitet.   | Basala prover, ENeG/EMG<br><u>Vaskulitprover:</u> CCP, SSA/SSB, ANCA. B-celler; komplement; Kryoglobiner; HCV, HIV.<br><u>Läppslemhinnebiopsi</u> (Sjögren?)<br><u>Malignitet:</u> DT thorax/buk; riktad malignitetsutredning efter symtom.<br>Paraneoplastiska ak.<br><u>Muskel, och ev. nervbiopsi</u> (vaskulit?)  |
| 6            | Degeneration av småkalibriga sensoriska kutana (Aδ + C) & ev. autonoma (C) fibrerna.<br>I de flesta fall är fintrådsneuropatin idiopatisk.<br>Identifierbara orsaker utgörs av metabola sjd såsom nedsatt glukostolerens, diabetes mellitus, Fabry och Tangiers sjd; Immunopatier (MGUS, vaskulit, SLE, Sjögrens syndrom, celiaki, paramalignitet och amyloidosis).<br>Toxiska faktorer (alkohol, vissa cytostatika, anti-HIV läkemedel, metronidazol och alkohol) samt Hereditära tillstånd (HSAN I, IV,V; CMT-IIb & ATTRv amyloidosis)  | Basala prover;<br>ENeG/EMG inklusive KST & ev. autonoma tester.<br>Vaskulitprover (se # 5)<br>Peroral glukosbelastning<br><br><b>Prog. måttligt-uttalade symtom även:</b><br><u>Celiakiutredning</u> (transglutaminas ak, px duodenum); Fettbiopsi (amyloidosis);<br><u>ev DNA analys för ATTRv amyloidosis</u><br><u>Ev Metabol-utredning:</u> Serum α-galaktosidase /u-trihexosid (Fabry); Blodfetter (Tangier)   |
| 7            | Axonal skada sekundärt till inflammation/ ischemi vid bindvävssjukdom, vaskulit och diabetes samt myelinskada på hereditär basis (HNPP).  | Basala prover, ENeG/EMG; LP<br>Vaskulitprover (se # 5); ev. DNA analys-HNPP. Muskel, och ev. även nervbiopsi (vaskulit?)  |

## Summary & Take Home

- Treating a patient with immune-mediated neuropathy is quite gratifying
- Ca 10-15% of polyneuropathies seen by neurologists at hospitals have an immune-mediated etiology
- Pattern recognition based on neurophysiology and topography:
  - Increases chances of etiological diagnosis and of treatment
  - More stimulating to investigate polyneuropathies!
- All that shines is not gold

Consider CMT1, HNPP, ATTRv, CANVAS, PSMA as diff. diagnosis

- Consider pan-neurofascin autoimmune neuropathy the next time you consult on a "GBS" patient with prolonged invasive ventilation in the ICU